ESR1 and breast carcinoma: When administered as an adjuvant therapy for primary treatment of estrogen receptor (ER)-sensitive breast cancer, tamoxifen was shown to reduce relapse and mortality rates (14), and to decrease recurrence rates in ER-positive breast cancer patients by 50% 15 years after diagnosis (13).